
Shares of genomic medicine firm Sangamo Therapeutics SGMO.O slide 19% to $0.46 premarket
SGMO announces pricing of $25 million stock sale at $0.4719 apiece
Company sold 35.2 million shares and pre-funded warrants to purchase 17.8 million shares in the offering
Proceeds from offering to be used for working capital and general corporate purposes
Cantor and Wells Fargo Securities are joint book-running managers for offering
Three of five brokerages rate the stock "buy" or higher and two "hold"; median PT $2 - data compiled by LSEG
As of last close, SGMO shares down 35.2% YTD